Traders Alert: Colgate-Palmolive, Ciena, Ross Stores, Horizon PharmaInovio Pharmaceuticals

Lakeway, NY -- (SBWIRE) -- 03/07/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Colgate-Palmolive Company (NYSE:CL) shares gained 1.60% to $117.20 in the pre-market hour after the Board of Directors of Colgate-Palmolive today approved a two-for-one split of the Company's common stock to be effected through a stock dividend and increased the ongoing quarterly cash dividend by 10%, both effective in second quarter 2013.

Is CL a Strong After The recent price Movement? Let’s Find out Here

Ciena Corporation (NASDAQ:CIEN) stock jumped 14.79% to $17.15 in the pre-market hour after the company today said its first-quarter GAAP net loss was $47.32 million, from last year's $47.7 million loss, with three-month loss per share reducing to $0.47, from $0.49 a year back. On a non-GAAP basis, Ciena's adjusted net income totaled $12.3 million, or $0.12 per share in the recent quarter. Analysts expected loss per share of $0.14 for the quarter. Quarterly revenue stood at $453.1 million, compared with last year's $416.7 million. Analysts estimated revenues of $449.14 million for the quarter.

Is CIEN a Strong Buying Opportunity After The Recent Slump? Find out Here

Ross Stores, Inc. (NASDAQ:ROST) stock fell 0.28% to $59.53 in the pre-market hour after the company today reported that sales increased 3% to $726 million for the four weeks ended March 2, 2013, up from $707 million for the four weeks ended March 3, 2012. Comparable store sales for the four weeks ended March 2, 2013 declined 1% versus the same period last year. This compared to a strong 9% gain for the four weeks ended February 25, 2012.

Is ROST Signaling a Buy Signal After The recent Volatility? Let’s Find out Here

Horizon Pharma Inc (NASDAQ:HZNP) shares climbed 10.24% to $2.05 in pre-market hour after the company today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for DUEXIS® (ibuprofen/famotidine) for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients who require regular treatment with high dose ibuprofen administered three times a day and who are at risk of developing non-steroidal anti-inflammatory drug (NSAID) associated gastric and/or duodenal ulcers

Is HZNP a Strong Buying Opportunity After The Recent Gain? Find out Here

Inovio Pharmaceuticals, Inc. (NYSEAMEX:INO) shares declined 26.10% to $0.510 in the pre-market hour after the company today priced an underwritten offering of 27,377,266 shares of its common stock and warrants to purchase up to 13,688,633 shares of common stock at a combined price to the public of $0.55 per share and related warrant for gross proceeds of $15.1 million. The warrants are exercisable at an exercise price of $.7936 per share and will expire, unless exercised, on the date that is 180 days after the fifth anniversary of the date of issuance.

Is INO a Still a Buy after the Solid momentum? Let’s Find out Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.